Acura Pharmaceuticals (ACUR) versus Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Financial Contrast

Acura Pharmaceuticals (OTCMKTS: ACUR) and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acura Pharmaceuticals -36.20% -231.18% -31.56%
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 44.47% 33.92% 8.94%

Earnings and Valuation

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acura Pharmaceuticals $4.46 million 1.82 -$7.38 million ($0.15) -2.60
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share $150.25 million 2.20 -$41.27 million $1.90 4.34

Acura Pharmaceuticals has higher earnings, but lower revenue than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

9.4% of Acura Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by institutional investors. 5.6% of Acura Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Acura Pharmaceuticals has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acura Pharmaceuticals 0 0 0 0 N/A
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 0 0 2 0 3.00

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a consensus target price of $25.00, indicating a potential upside of 203.03%. Given Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s higher probable upside, analysts clearly believe Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share is more favorable than Acura Pharmaceuticals.

Summary

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share beats Acura Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

What are top analysts saying about Acura Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acura Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit